CU20200075A7 - Antígeno quimérico que comprende el dominio extracelular de pd-l1 - Google Patents

Antígeno quimérico que comprende el dominio extracelular de pd-l1

Info

Publication number
CU20200075A7
CU20200075A7 CU2020000075A CU20200075A CU20200075A7 CU 20200075 A7 CU20200075 A7 CU 20200075A7 CU 2020000075 A CU2020000075 A CU 2020000075A CU 20200075 A CU20200075 A CU 20200075A CU 20200075 A7 CU20200075 A7 CU 20200075A7
Authority
CU
Cuba
Prior art keywords
chimeric antigen
extracellular domain
multimer
receptors
ligand
Prior art date
Application number
CU2020000075A
Other languages
English (en)
Other versions
CU24705B1 (es
Inventor
Ávila Marta Ayala
Romero Mónica Bequet
Pérez Vladimir Armando Besada
Ayala Camila Canaán-Haden
Rodríguez Luis Ariel Espinosa
COWLEY Jorge Víctor GAVILONDO
Blanco Sonia González
Moya Isabel González
Fernández Miladys Limonta
DÍAZ Yanelys MORERA
Ramírez Javier Sánchez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000075A priority Critical patent/CU24705B1/es
Priority to CN202180072039.2A priority patent/CN116783221A/zh
Priority to PCT/CU2021/050008 priority patent/WO2022083805A1/es
Priority to CA3196460A priority patent/CA3196460A1/en
Priority to EP21806135.6A priority patent/EP4234029A1/en
Priority to US18/033,035 priority patent/US20230390369A1/en
Priority to KR1020237015994A priority patent/KR20230107810A/ko
Priority to AU2021363436A priority patent/AU2021363436A1/en
Priority to JP2023524660A priority patent/JP2023546485A/ja
Priority to MX2023004718A priority patent/MX2023004718A/es
Publication of CU20200075A7 publication Critical patent/CU20200075A7/es
Publication of CU24705B1 publication Critical patent/CU24705B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Antígeno quimérico que comprende el dominio extracelular del ligando 1 del receptor proteico de muerte celular programada 1 (PD-L1) humano y que forma un multímero que tiene reducida la capacidad de unión a los receptores PD-1 y CD80 respecto a la forma nativa de PD-L1. La composición farmacéutica que comprende dicho antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable.</p>
CU2020000075A 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1 CU24705B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN202180072039.2A CN116783221A (zh) 2020-10-22 2021-09-28 包含pd-l1的胞外结构域的嵌合抗原
PCT/CU2021/050008 WO2022083805A1 (es) 2020-10-22 2021-09-28 Antígeno quimérico que comprende el dominio extracelular de pd-l1
CA3196460A CA3196460A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
EP21806135.6A EP4234029A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
US18/033,035 US20230390369A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
KR1020237015994A KR20230107810A (ko) 2020-10-22 2021-09-28 Pd-l1의 세포 외 도메인을 포함하는 키메라 항원
AU2021363436A AU2021363436A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
JP2023524660A JP2023546485A (ja) 2020-10-22 2021-09-28 Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
MX2023004718A MX2023004718A (es) 2020-10-22 2021-09-28 Antigeno quimerico que comprende el dominio extracelular de pd-l1.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Publications (2)

Publication Number Publication Date
CU20200075A7 true CU20200075A7 (es) 2022-05-11
CU24705B1 CU24705B1 (es) 2024-06-11

Family

ID=78598633

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Country Status (10)

Country Link
US (1) US20230390369A1 (es)
EP (1) EP4234029A1 (es)
JP (1) JP2023546485A (es)
KR (1) KR20230107810A (es)
CN (1) CN116783221A (es)
AU (1) AU2021363436A1 (es)
CA (1) CA3196460A1 (es)
CU (1) CU24705B1 (es)
MX (1) MX2023004718A (es)
WO (1) WO2022083805A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
WO2014183649A1 (zh) 2013-05-14 2014-11-20 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
US11339201B2 (en) * 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
JP7247097B2 (ja) 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
US20230390369A1 (en) 2023-12-07
MX2023004718A (es) 2023-05-10
AU2021363436A1 (en) 2023-06-01
AU2021363436A9 (en) 2024-10-10
EP4234029A1 (en) 2023-08-30
CA3196460A1 (en) 2022-04-28
KR20230107810A (ko) 2023-07-18
JP2023546485A (ja) 2023-11-02
CN116783221A (zh) 2023-09-19
CU24705B1 (es) 2024-06-11
WO2022083805A1 (es) 2022-04-28

Similar Documents

Publication Publication Date Title
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
PE20190115A1 (es) Anticuerpos vista antihumanos y su uso
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
CL2018000983A1 (es) Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).
CL2021001153A1 (es) Receptores de antígenos quiméricos específicos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteína g (gprc5d)
PE20220220A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
PE20241349A1 (es) Anticuerpos de union a cd3
BR112019014986A2 (pt) anticorpo que alveja bcma e uso do mesmo
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CR20190050A (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CO2017000510A2 (es) Constructos de car
CL2016001723A1 (es) Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos.
AR112902A1 (es) Receptores de células t restringidas a hla de clase ii contra ras mutado
CY1124913T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
UY35712A (es) Anticuerpos anti-prlr y uso de los mismos
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
AR093788A1 (es) Inmunoterapia con agentes de enlace
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
PE20160225A1 (es) Modulacion de la inmunidad tumoral
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
CL2021002986A1 (es) Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias